Skip to content

An Exploring on "Concentration-Volume-Dose" of Bupivacaine Liposome in Analgesia Efficacy and Ankle Muscle Strength for Sciatic Nerve Block after TKA and it's Mechanism of Neurotoxicity studying.

An Exploring on "Concentration-Volume-Dose" of Bupivacaine Liposome in Analgesia Efficacy and Ankle Muscle Strength for Sciatic Nerve Block after TKA and it's Mechanism of Neurotoxicity studying.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112847
Enrollment
Unknown
Registered
2025-11-20
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Interventions

High-Concentration and Low-Volume Group:Drug dilution
Medium-Concentration -Volume Group:Drug dilution
Low-Concentration and High-Volume Group:Drug dilution

Sponsors

Foshan Fosun Chancheng Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 80 Years

Inclusion criteria

Inclusion criteria: A total of 120 patients of both sexes, aged 55-80 yr, of American Society of Anesthesiologists physical status II or III, with body mass index of 18-27 kg/m2, scheduled for unilateral TKA under combined spinal-epidural anesthesia in our hospital from November 2025 to August 2027, were selected. Peripheral nerve block analgesia was performed under ultrasound guidance after operation.

Exclusion criteria

Exclusion criteria: 1. Pregnancy, or presence of neuropathic or neuromuscular diseases. 2. History of severe cardiovascular or cerebrovascular diseases, hepatic or renal dysfunction, cerebral stroke, or peptic ulcer disease. 3. Allergy to local anesthetics or opioids. 4. Communication disability, or history of psychological or psychiatric disorders. 5. Contraindications to regional nerve block (e.g., coagulopathy, local infection at the injection site). 6. History of alcohol abuse, or use opioid or sedative medications preoperatively.

Design outcomes

Primary

MeasureTime frame
RVAS & MVAS; Lower Extremity Muscle Strength (Motor and Sensory Function);

Countries

China

Contacts

Public ContactMeirong Wang

Foshan Fosun Chenzheng Hospital

wangmrong1217@163.com+86 139 2724 1475

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026